Perioperative suppression of NK activity has been suggested to compromise host resistance to tumor progression. Here, we sought to develop a clinically applicable preoperative regimen to prevent immunosuppression and promotion of metastasis by stress or surgery. The synthetic ds-RNA, poly I-C, was used in vivo in F344 rats, based on its alleged in vitro ability to protect immunocytes from suppression by cAMP elevating agents. Different regimens of poly I-C were studied in controls and in rats subjected to a pharmacological stressor, swim stress, or surgical stress. Resistance to lung experimental metastasis of the syngeneic non-immunogenic MADB106 mammary adenocarcinoma was assessed. Numbers of circulating and marginating-pulmonary NK cells and their cytotoxicity against the MADB106 and YAC-1 target lines were also studied. Our findings established a regimen of repeated low-dose poly I-C administration with minimal side effects (0.2 mg/kg i.p. 5, 3, and 1 day before tumor inoculation). This regimen, while hardly affecting resistance levels in non-stressed animals, prevented all stressors from promoting metastases. These beneficial effects occurred in the presence of a primary tumor and in both sexes. Poly I-C increased the numbers of NK cells, and, on a per NK cell basis, while not increasing cytotoxicity, profoundly protected marginating-pulmonary NK cells from suppression by surgery. This study suggests a non-toxic clinically translatable prophylactic use of poly I-C to target the critical perioperative period. By increasing the number of marginating-pulmonary NK cells, and by transforming them into a mode of resistance to immunosuppression, this approach may reduce postoperative metastasis in cancer patients.
Introduction
Metastasis is the leading cause of death in cancer patients. Excision of the primary tumor is a mainstay of therapy in many tumor types, but may promote spread and seeding of malignant cells and growth of pre-existing micrometastases in some cancers (Sugarbaker, 2005; Thompson et al., 2005) . Mechanisms that may mediate these adverse effects of surgery, independently or synergistically, include dissemination of malignant cells due to the mechanical manipulation of the primary tumor or its vascularization (Weitz and Herfarth, 2001 ), a drop in the systemic levels of tumor-related anti-angiogenic factors (Zetter, 1998) , excess release of growth factors and proangiogenic factors (Hofer et al., 1999; Lutgendorf et al., 2003) , and perioperative suppression of cell mediated immunity (Little et al., 1993 
